About PT-141
Human randomized trials · Controlled study formulation
What it is studied for
Also known as bremelanotide, a melanocortin receptor agonist studied in sexual-desire signaling.
What selected research found
Two 2019 phase 3 trials in premenopausal women with hypoactive sexual desire disorder reported improved desire scores and reduced related distress versus placebo. Nausea, flushing and headache were more common.
Evidence limits
Those results concern a specific clinical population and formulation. They do not establish benefits for all sexes or equivalence of this research material to a prescription medicine.
Selected sources
References reviewed October 10, 2026.
Research use only. These notes summarize selected publications; they are not a systematic review, medical advice, dosing instructions, or evidence about this product lot. Clinical studies used controlled study formulations and supervision. AuraBio materials are not for human or veterinary use. Review the exact material identity and available lot documentation for your laboratory application.






Reviews
There are no reviews yet.